title: Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators.
abstract: OBJECTIVE
  This study was performed to characterize the risk of stroke in elderly patients with recurrent intermittent atrial fibrillation (AF).
  
  
  BACKGROUND
  Although intermittent AF is common, relatively little is known about the attendant risk of stroke.
  
  
  METHODS
  A longitudinal cohort study was performed comparing 460 participants with intermittent AF with 1,552 with sustained AF treated with aspirin in the Stroke Prevention in Atrial Fibrillation studies and followed for a mean of two years. Independent risk factors for ischemic stroke were identified by multivariate analysis.
  
  
  RESULTS
  Patients with intermittent AF were, on average, younger (66 vs. 70 years, p < 0.001), were more often women (37% vs. 26% p < 0.001) and less often had heart failure (11% vs. 21%, p < 0.001) than those with sustained AF. The annualized rate of ischemic stroke was similar for those with intermittent (3.2%) and sustained AF (3.3%). In patients with intermittent AF, independent predictors of ischemic stroke were advancing age (relative risk [RR] = 2.1 per decade, p < 0.001), hypertension (RR = 3.4, p = 0.003) and prior stroke (RR = 4.1, p = 0.01). Of those with intermittent AF predicted to be high risk (24%), the observed stroke rate was 7.8% per year (95% confidence interval 4.5 to 14).
  
  
  CONCLUSIONS
  In this large cohort of AF patients given aspirin, those with intermittent AF had stroke rates similar to patients with sustained AF and similar stroke risk factors. Many elderly patients with recurrent intermittent AF have substantial rates of stroke and likely benefit from anticoagulation. High-risk patients with intermittent AF can be identified using the same clinical criteria that apply to patients with sustained AF.
authors.affiliation: Department of Medicine, University of Texas Health Science Center, San Antonio 78284, USA. HartR@uthscsa.edu
authors.forename: R G
authors.initials: RG
authors.lastname: Hart
authors.forename: L A
authors.initials: LA
authors.lastname: Pearce
authors.forename: R M
authors.initials: RM
authors.lastname: Rothbart
authors.forename: J H
authors.initials: JH
authors.lastname: McAnulty
authors.forename: R W
authors.initials: RW
authors.lastname: Asinger
authors.forename: J L
authors.initials: JL
authors.lastname: Halperin
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000150:complications*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D014859:Warfarin; D001241:Aspirin